Utama › Kanser Tiroid › California
Kajian klinikal Kanser Tiroid di California
14 kajian untuk Kanser Tiroid sedang mencari peserta di lokasi di California.
Bandar di California
Teks kajian rasmi (Bahasa Inggeris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- PCR Oncology, Arroyo Grande
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- dan 20 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069DESTINY-PANTUMOUR04
- Research Site, San Diego
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 130 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07124000Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- The Angeles clinic - A cedars SINAI AFFILIATE, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
- University of California, San Francisco (UCSF), San Francisco
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT05786924Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
- The Unviersity of California, San Francisco (UCSF), San Francisco
Mengambil pesertaFasa 2
Umur 2 hingga 25 · Semua jantina · Dikemas kini 24 Jul 2026 · NCT06458036Navigation Intervention for Adolescent and Young Adult Cancer Survivors
- KP Southern California - Department of Research & Evaluation, Pasadena
Mengambil peserta
Umur 21 hingga 45 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT07406087Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
- University of California, San Francisco, San Francisco
Mengambil pesertaFasa 2
Umur 13 ke atas · Semua jantina · Dikemas kini 18 Jun 2026 · NCT06961084A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- St Joseph Heritage Healthcare, Santa Rosa
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116Active Surveillance of Papillary Thyroid Microcarcinoma
- Cedars-Sinai Medical Center, Los Angeles
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mei 2026 · NCT02609685Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
- City of Hope, Duarte
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Institute, Stanford
Mengambil pesertaFasa 1
Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Mac 2026 · NCT04119024Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Mac 2026 · NCT04742608Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
- City of Hope Medical Center, Duarte
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Feb 2026 · NCT05229341cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- City of Hope, Duarte
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- University of California, San Francisco, San Francisco
Mengambil pesertaFasa 2
Umur 2 hingga 99 · Semua jantina · Dikemas kini 14 Nov 2025 · NCT05783323APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Jun 2025 · NCT03175224Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.